Shedding at TATAA Biocenter
Advancing PCR bioanalysis

Shedding of gene therapy products

At TATAA Biocenter, we collaborate closely with you to custom-design assays that accurately detect your shed products in excreta, secreta, or skin swabs. Our highly sensitive assays are validated to be in line with regulatory requirements.

Shedding guided by FDA and EMA

Preclinical and clinical shedding

Digital PCR (dPCR) outperforms quantitative PCR for shedding. We develop, optimize, and validate highly sensitive dPCR assays for shedding assessments. The assay sensitivity is critical when dealing with shed nucleic acids from replication-incompetent viral vectors, often present in very low copy numbers. The matrices in which these nucleic acids are found pose additional challenges, including DNA-degrading enzymes, PCR-inhibitory substances, and high levels of genetic background from endogenous flora and environmental microorganisms. We routinely overcome these challenges.

Shedding instruments
Shedding FDA

Recommendations and analysis of shedding studies by FDA and EMA

At TATAA Biocenter, we adhere to FDA and EMA guidelines, which mandate the study of preclinical and clinical shedding to mitigate the risk of transmission to untreated individuals. Our assays are designed to offer the sensitivity needed to detect shedding across various matrices, such as excreta, secreta, or the skin. The selection of these matrices is based on the nature of the product, its tropism, and the route of administration.

Immunoprofiling

Immunological considerations

Pre-existing immunity, or immune priming during repeated administrations, can significantly affect drug efficacy, necessitating immunity testing to ensure reliable data. Using only microliters of plasma or blood samples, we use Olink Target 48 Cytokine panels to monitor the activation of the innate immune response through absolute quantification of key cytokines.

Stay in touch

Sign up for our newsletter

test

"*" indicates required fields

Name*

PCR technologies, such as quantitative PCR (qPCR) and particularly digital PCR (dPCR), are critical tools for AAV shedding assays. They offer the high sensitivity and specificity essential for assessing viral load across various sample types. Open application note in PFD

Viral shedding assays presents unique challenges. The analytes released are typically found in very low quantities, and the matrices involved in shedding assays often contain significant levels of PCR inhibitory agents and endogenous DNA. Our shedding services The FDA requires

Shedding assays require optimized extraction protocols tailored for each sample type and an accurate qPCR/dPCR assay with the necessary sensitivity and specificity. This ensures that shed products are detected and the risk of transmission to a third party is mitigated.

About us

The power of our approach

Committed to quality, innovation, and fostering strong client relationships, we serve as your trusted partner to accelerate drug development. As a contract research organization, our mission is to push the boundaries of science and technology to generate accurate and reproducible data that shortens time-to-market.

Regulated laboratory environment

We are GLP accredited for qPCR, dPCR, and molecular biology, GCLP compliant, and ISO/IEC 17025 accredited. Our facility features a strict sample management process, a fully integrated LIMS system, backup for all vital systems, temperature and humidity control, and robust IT security.

Purpose-built PCR laboratory

Our purpose-built laboratory in Gothenburg, Sweden, is specifically designed for PCR. It has controlled air pressure, temporal separation, and biosafety cabinets to minimize contamination risk. This setup enables us to achieve the highest sensitivity and robustness required for validated assays. The lab is equipped with market-leading PCR and NGS instruments and advanced liquid handling systems.

Pioneers in assay development and validation

We are a team of 45 employees, with scientists at the forefront of assay development, optimization, and validation. Our team has co-authored key publications in the field, including Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development (AAPS J. 2024) and The MIQE Guidelines for qPCR and dPCR.

Flexible, client-centered solutions

We work closely with our clients to find tailored solutions, offering flexibility in sample types, test items, sample volume, and scalability. We prioritize transparency and proactive communication throughout each project, ensuring our clients are continuously updated on the progress.

contact

Let's explore how we can support your drug development program.

PK/PD​ bioanalysis

One form for all pages, including link to mailchimp.

"*" indicates required fields

×

Olink

"*" indicates required fields

What platform of interest?*
Name*

General Enquiries

Please fill in the form below and we’ll get back to you ASAP.

"*" indicates required fields

Name*

Courses

Please fill in the form for any courses request

"*" indicates required fields

Name*

Sign up to our Newsletter

"*" indicates required fields

Name*

Bioanalytical Services

Please fill in the form below and one of our bioanalytical experts will get back to you ASAP.

"*" indicates required fields

What services are you interested in?*
This field is hidden when viewing the form

Products

Please fill in the form below for any products request

"*" indicates required fields